

Rec'd PCT/PTO 13 AUG 2002

PATENT

#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of
DARTEIL

Application No.: **10/018,729**

Filed: **DECEMBER 18, 2001**

Title: **SYSTEM OR REGULATION OF
EXPRESSION USING PPAR
NUCLEAR RECEPTOR**



Examiner: **UNASSIGNED**

Art Unit: **UNASSIGNED**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

AUGUST 5, 2002

Date of deposit

Signature

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Aventis Docket No. ST99021 US PCT